Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
5.4
Journals
Pharmaceutics
Special Issues
Nano-Vaccine Systems for Anti-cancer Therapy
share announcement

Nano-Vaccine Systems for Anti-cancer Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 4925

Special Issue Editors

Prof. Dr. Chong-Su Cho

E-Mail Website
Guest Editor
Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, 1 Gwanangno, Gwanak-gu, Seoul 08826, Korea
Interests: nanoparticle; nanotechnology; adjuvant; nanovaccinology; polymeric vaccine
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. In-Kyu Park

E-Mail Website
Guest Editor
Department of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 61469, Korea
Interests: nanoparticles mediated delivery of therapeutic drug and genes; bio-compatible hydrogels
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Even though chemotherapy is one of the commonly used therapeutic clinical strategies to treat cancer, its effectiveness is limited due to steep dose–response relationships, narrow therapeutic windows, and non-specific organ toxicity. Therefore, we need to develop more effective anti-cancer strategies. Preclinical findings regarding adaptive immune cancer therapy are very impressive, but their translation into clinics has not been very successful so far. One of the major reasons for this is the high complexity of the tumor microenvironment. The immune-suppressive property of tumors makes them inhospitable for anti-tumor immune effector cells, hindering their action against cancer cells. Recent advances in science and technology have led to the development of a variety of delivery systems such as cancer nano-vaccines capable of generating robust antitumor immune responses.  These systems are responsive to variations in pH, redox potential, enzymatic activation, thermal gradients, magnetic fields, light, and ultrasounds (US). They can even be tailored to be responsive to dual or multiple stimuli. Topics of interest for this Special Issue are natural and synthetic tumor microenvironment-responsive nanoparticles as cancer vaccine delivery systems, anti-tumor immunity-eliciting nanoparticles, and other nano-systems stimulating anti-cancer immune responses.

Prof. Dr. Chong-Su Cho
Prof. Dr. In-Kyu Park
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nano-carriers for anti-cancer vaccine applications 
  • Tumor microenvironment-responsive anti-cancer nano-vaccines 
  • External and internal stimuli-responsive anti-cancer nano-vaccines 
  • Combinational anti-cancer vaccine therapy 
  • Remodeling of tumor microenvironment for anti-cancer nano-vaccines

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 2421 KiB  
Article
Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages
by Maarten K. Nijen Twilhaar, Lucas Czentner, Joanna Grabowska, Alsya J. Affandi, Chun Yin Jerry Lau, Katarzyna Olesek, Hakan Kalay, Cornelus F. van Nostrum, Yvette van Kooyk, Gert Storm and Joke M.M. den Haan
Pharmaceutics 2020, 12(12), 1138; https://doi.org/10.3390/pharmaceutics12121138 - 25 Nov 2020
Cited by 16 | Viewed by 4542
Abstract
Despite promising progress in cancer vaccination, therapeutic effectiveness is often insufficient. Cancer vaccine effectiveness could be enhanced by targeting vaccine antigens to antigen-presenting cells, thereby increasing T-cell activation. CD169-expressing splenic macrophages efficiently capture particulate antigens from the blood and transfer these antigens to [...] Read more.
Despite promising progress in cancer vaccination, therapeutic effectiveness is often insufficient. Cancer vaccine effectiveness could be enhanced by targeting vaccine antigens to antigen-presenting cells, thereby increasing T-cell activation. CD169-expressing splenic macrophages efficiently capture particulate antigens from the blood and transfer these antigens to dendritic cells for the activation of CD8+ T cells. In this study, we incorporated a physiological ligand for CD169, the ganglioside GM3, into liposomes to enhance liposome uptake by CD169+ macrophages. We assessed how variation in the amount of GM3, surface-attached PEG and liposomal size affected the binding to, and uptake by, CD169+ macrophages in vitro and in vivo. As a proof of concept, we prepared GM3-targeted liposomes containing a long synthetic ovalbumin peptide and tested the capacity of these liposomes to induce CD8+ and CD4+ T-cell responses compared to control liposomes or soluble peptide. The data indicate that the delivery of liposomes to splenic CD169+ macrophages can be optimized by the selection of liposomal constituents and liposomal size. Moreover, optimized GM3-mediated liposomal targeting to CD169+ macrophages induces potent immune responses and therefore presents as an interesting delivery strategy for cancer vaccination. Full article
(This article belongs to the Special Issue Nano-Vaccine Systems for Anti-cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop